Atomoxetine for the treatment of attention-deficit/hyperactivity disorder;Atomoxetin in der behandlung der aufmerksamkeitsdefizit-/ hyperaktivitätsstörung bei kindern und erwachsenen

Fortschritte der Neurologie Psychiatrie

Volumn 72, Issue 10, 2004, Pages 586-591

  Davids, Eugen ^a   Gastpar, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR;

ADDICTION RESEARCH CENTER INVENTORY; ADHD IV RATING SCALE; ADJECTIVE RATING SCALE; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONNER ADULT ADHD RATING SCALE; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; NERVE ENDING; OPEN STUDY; PHARMACODYNAMICS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UNITED STATES; VISUAL ANALOG SCALE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS; DEVICE APPROVAL; FEMALE; HUMANS; MALE; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 6344284548     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830049     Document Type: Article

References (49)

1. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121: 65-94
2. Castellanos FX. Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr 1997; 36: 381-393
3. Internationale Klassifikation psychischer Störungen, ICD-10, Kapitel V (F), Weltgesundheitsorganisation. Göttingen: Verlag Hans Huber, 1991
4. Amercian Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edit. Washington, DC, 1994
5. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990; 29: 546-557
6. Gallagher R, Blader J. The diagnosis and neuropsychological assessment of adult attention deficit/hyperactivity disorder. Ann N Y Acad Sci 2001; 931: 148-171
7. Groß J, Blocher D, Trott GE, Rösler M. Erfassung des hyperkinetischen Syndroms bei Erwachsenen. Nervenarzt 1999; 70: 20-25
8. Krause KH, Krause J, Trott GE. Das hyperkinetische Syndrom (Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung) des Erwachsenenalters. Nervenarzt 1998; 69: 543-556
9. Blocher D, Henkel K, Retz W, Retz-Junginger P, Thome J, Rösler M. Symptome aus dem Spektrum des hyperkinetischen Synrdoms bei Sexualdelinquenten. Fortschr Neurol Psychiat 2001; 69: 453-459
10. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951-958
11. FDA. Strattera approved to treat ADHD. FDA Consum 2003; 37: 4
12. Fritze J, Schmauss M. [Off-label use: the case of methylphenidate (Ritalin)]. Nervenarzt 2002; 73: 1210-1212
13. Preti A. Tomoxetine. Curr Opin Investig Drugs 2002; 3: 272-277
14. Zerbe RL, Rowe H, Enas GG, Wong D, Farid N, Lemberger L. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985; 232: 139-143
15. Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, Malone M, Ickowicz A, Schachar R, Tannock R, Kennedy JL. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am J Med Genet 2002; 114: 255-259
16. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder as a noradrenergic disorder. Biol Psychiatry 1999; 46: 1234-1242
17. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63 Suppl 12: 3-9
18. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003; 4: 1165-1174
19. Simpson D, Perry CM. Atomoxetine. Paediatr Drugs 2003; 5: 407-415
20. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003; 64: 110-111
21. 3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett; 157: 203-206
22. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention-deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699-711
23. Garces K. Atomoxetine for attention deficit/hyperactivity disorder. Issues Emerg Health Technol 2003; 46: 1-4
24. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002; 30: 319-323
25. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31: 98-107
26. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYD2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002; 42: 1219-1227
27. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985; 25: 296-301
28. Witcher JW, Long A, Smith B, Sauer JM, Heiligenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 53-63
29. Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003; 73: 178-191
30. Wernicke J, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-740
31. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl 12: 50-55
32. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989; 28: 777-784
33. Otka JE, Mercadante MT, Scahill L, Leckman JF. Reboxetine as a potentially effective treatment for attention defcit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11: 203-204
34. Pliszka SR. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 2003; 8: 253-258
35. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 605-646
36. Schweitzer JB, Holcomb HH. Drugs under investigation for attention-deficit hyperactivity disorder. Curr Opin Investig Drugs 2002; 3: 1207-1211
37. Spencer TJ, Biederman J. Non-stimulant treatment for Attention-Deficit/ Hyperactivity Disorder. J Atten Disord 2002; 6: S109-119
38. Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SV. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002; 59: 649-656
39. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002; 63 Suppl 12: 16-22
40. Spencer TJ, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155: 693-695
41. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11: 251-265
42. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-784
43. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63: 1140-1147
44. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: e83
45. Michelson D, Alien AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-1901
46. Bukstein OG. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder in children and adolescents. Evid Based Ment Health 2003; 6: 42
47. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Alien AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with ADHD: two randomized placebo-controlled studies. Biol Psychiatry 2003; 53: 112-120
48. Heinzl S. Atomoxetin für Kinder und Erwachsene mit ADHS. Psychopharmakotherapie 2003; 10: 120-124
49. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67: 149-156